Azitra, Inc.
Close on Oct 19, 2026
- Market cap
- $1.38M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | $-0.17 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 27, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | $-0.18 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 24, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | $0 | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 15, 2024 | After market close | – | – | – |
Press releases
Announcements Azitra filed with the SEC
Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
Other events · EX-99.1 to Form 8-K
Inc. to Present at the H.C. Wainwright 28 th Annual Global Investment Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Regains Compliance with NYSE American Continued Listing Standards
Other events · EX-99.1 to Form 8-K
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for
Other events · EX-99.1 to Form 8-K
Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
Other events · EX-99.1 to Form 8-K
Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
Other events · EX-99.1 to Form 8-K
Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
Other events · EX-99.1 to Form 8-K
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
Listing notice · Other events · EX-99.1 to Form 8-K
Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
Results of operations · EX-99.9 to Form 8-K
Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Other events · EX-99.1 to Form 8-K
Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Listing notice · Other events · EX-99.1 to Form 8-K
Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Receives Notice of Non-Compliance from NYSE American
Listing notice · Other events · EX-99.1 to Form 8-K
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
RELATED TO ANNUAL MEETING OF STOCKHOLDERS
Other events · EX-99.1 to Form 8-K
Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Q1 2025 Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Inc. Announces Full Year 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Proposed Public Offering of Common Stock
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces Pricing of $1.5 Million Public Offering of Common Stock
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Inc. Announces Q3 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Q2 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Conn., July 23, 2024--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical
Material agreement · Other events · EX-99.1 to Form 8-K
Conn., July 25, 2024--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical
Material agreement · Other events · EX-99.2 to Form 8-K
Inc. Announces Q1 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Pricing of Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Announces Third Quarter 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Second Quarter 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Pricing of Initial Public Offering
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Closing of Initial Public Offering
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K